Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$272.60 USD

272.60
840,837

+1.41 (0.52%)

Updated Sep 16, 2025 03:59 PM ET

Pre-Market: $273.28 +0.68 (0.25%) 9:04 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Cerner (CERN) Earnings Beat Estimates in Q3, Improve Y/Y

by Zacks Equity Research

Cerner (CERN) Q3 results benefit from higher revenues, gains in Licensed software, Technology resale, Professional and Managed services units, and international revenue growth.

Zacks Equity Research

NextGen (NXGN) Q2 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

NextGen (NXGN) retains its fiscal 2020 revenue and EPS guidance.

Zacks Equity Research

GNC Holdings (GNC) Q3 Loss Meets Estimates, Revenues Miss

by Zacks Equity Research

GNC Holdings' (GNC) third-quarter 2019 results, reflecting dismal performance across segments, disappoint investors.

Zacks Equity Research

Illumina (ILMN) Beats Q3 Earnings Estimates, Raises View

by Zacks Equity Research

Illumina (ILMN) announces impressive Q3 results on the back of strong growth in the sequencing business.

Zacks Equity Research

3 Reasons Growth Investors Will Love ResMed (RMD)

by Zacks Equity Research

ResMed (RMD) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

ResMed (RMD) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

ResMed (RMD) delivered earnings and revenue surprises of 6.90% and 3.63%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Edwards Lifesciences (EW) Beats on Q3 Earnings, Ups EPS View

by Zacks Equity Research

Edwards Lifesciences (EW) reports strong Q3 sales on the recent FDA indication expansion of SAPIEN 3 and SAPIEN 3 Ultra systems.

Zacks Equity Research

Varian (VAR) Earnings and Revenues Surpass Estimates in Q4

by Zacks Equity Research

Varian (VAR) gains from core Oncology segment's solid contribution in fiscal Q4.

Zacks Equity Research

Thermo Fisher (TMO) Beats on Q3 Earnings, Lifts Guidance

by Zacks Equity Research

We are encouraged that three out of Thermo Fisher's (TMO) four business segments have registered strong year-over-year revenue growth in Q3.

Zacks Equity Research

Medical Products' Oct 24 Earnings Roster: BAX, CERN & More

by Zacks Equity Research

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Zacks Equity Research

Should You Buy ResMed (RMD) Ahead of Earnings?

by Zacks Equity Research

ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

ResMed Upgrades Nasal Care by Introducing Cradle CPAP Mask

by Zacks Equity Research

ResMed (RMD) revolutionizes sleep apnea treatment by introducing a hassle-free and easy-to-use mask.

Trina Mukherjee headshot

Medical Products Industry Outlook: Prospects Seem Promising

by Trina Mukherjee

Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.

Urmimala Biswas headshot

3 Medical Product Stocks Likely to Beat This Earnings Season

by Urmimala Biswas

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

Zacks Equity Research

ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

ResMed (RMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Trina Mukherjee headshot

Sleep Apnea Market Gains Momentum: 3 Stocks in Focus

by Trina Mukherjee

Sleep apnea - a significant health issue in the United States - is a booming market, thereby reflecting promising investment prospects.

Zacks Equity Research

GNNDY or RMD: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GNNDY vs. RMD: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors' confidence continues to be high on ResMed's (RMD) prospects.

Zacks Equity Research

ResMed (RMD) Up 6.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

ResMed (RMD) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

ResMed (RMD) gains from promising financial results in the fourth quarter of fiscal 2019.

Zacks Equity Research

NUVA vs. RMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

NUVA vs. RMD: Which Stock Is the Better Value Option?

Zacks Equity Research

ResMed's (RMD) Q4 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

ResMed (RMD) achieves double-digit global revenue growth in the fourth quarter, led by strong sales at Software-as-a-Service businesses as well as of new mask products and devices.

Zacks Equity Research

ResMed (RMD) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

ResMed (RMD) delivered earnings and revenue surprises of 3.26% and 0.47%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products' Earnings Roster for Jul 25: SYK, BAX & More

by Urmimala Biswas

Encouraging growth in the emerging markets is likely to be a bonus for the medical products space this earnings season.

Zacks Equity Research

Analysts Estimate ResMed (RMD) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.